

Clinical Trials Cost Less in China than US

Phase I and Phase II - Single Country Trials

30 → 50%

Phase I Cost Saving
China vs US across TAs

15% → 30%

Phase II Cost Saving
China vs US across TAs

\$2.51M

Average Phase I Saving
\$3.29M vs \$5.80M

52%


Largest Gap: Inf Disease
\$3.6M vs \$7.58M

TRIAL COST BY THERAPY AREA

Phase I - Average Cost of Clinical Trials

Cost in \$ millions - single-country trials


● United States ● China



Phase II - Average Cost of Clinical Trials


Cost in \$ millions - single-country trials

● United States ● China




COST SAVINGS BY THERAPY AREA

Phase I



Phase II



KEY FINDINGS

Phase I trials are 30–50% less expensive in China compared to the US, likely driven by lower site costs and operational expenses.


This trend is consistent across all therapy areas suggesting incentive to run clinical trials in China.

Acronyms

CNS - Central Nervous System
Infectious - Infectious disease
NBA - New Biological Entity

NMA - New Molecular Entity
Metabolic - Metabolic Disorder

TOTAL COST SAVINGS



Cost savings are driven by lower site costs and operational expenses, with savings narrowing as trial complexity increases.